Lysa Lymphoma presentation #ASH20! Romidepsin with CHOP does not significantly prolong PFS in untreated PTCL. Tox. of romidepsin partly hampers adequate administration of CHOP. Exploratory analyses in specific subgroups to come especially in centrally confirmed Tfh-phenotype PTCL

[LYSA days] The sixth edition of LYSA Days will take place from Sept. 2 to 4 in Rennes. Along with LYSA members’ presentations, we will have the pleasure of welcoming 4 scientific guests! Stayed tuned for more! CHU de Rennes Le Couvent Rennes #LYSARennes2021

Congrats Emmanuel Bachy et al!

📢LYSA oral now #ASH21 Emmanuel Bachy Stringent propensity score-matched analysis btw axi-cel & tisacel from DESCAR-T registry ✅higher CR rates & prolonged PFS w/ axi-cel ✅no diff. in DOR or OS ✅less toxicity (ICANS) w/ tisacel Could help select what better CAR for which ptt

📢Edith Julia presenting now #ASH21 for Lysa Lymphoma! ➡️ATAC-seq to refine cell-of-origin classification of mature T-cell lymphomas and increase diagnostic accuracy by detection of subtype-specific epigenetic profiles, viral sequences and CNV Emmanuel Bachy

[LYSA publication Nature Medicine] « A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B-cell lymphoma » By Emmanuel Bachy, Morschhauser Steven Le Gouill Roch Houot on DESCAR-T youtube.com/watch?v=I_m7dp…

Delighted that #glofitamab pivotal data for DLBCL is now online NEJM. 39.4% CR in patients with the most common aggressive #lymphoma, Fixed course, durable remissions, good safety profile, I hope this data changes practice for patients with R/R #DLBCL #ASH22 #lymsm Martin Hutchings

[LYSA publication Journal of Clinical Oncology] “With 6 yrFU ‘Ro-CHOP’ study still negativebut potential benefitof romidepsinin TFH-PTCL and BV+chemo at relapse“ Publication by Vincent Camus & Emmanuel Bachy ascopubs.org/doi/10.1200/JC…